Abstract 83P
Background
Treatment (tx) options for patients (pts) with Von Hippel-Lindau syndrome (VHL) were previously limited to surgeries between regular scans, observation and txs that preserve organ function. Little data exists on the burden of VHL-associated tumor tx on the mental health of pts.
Methods
International, cross-sectional survey comprising pts in the United States, Canada, UK, France, and Germany. Pts recruited via the VHL Alliance. Pts must have renal cell carcinoma (RCC), pancreatic neuroendocrine tumors (pNET), and/or central nervous system hemangioblastoma (CNS Hb). Data collected included demographics, impact of most recent surgery on aspects of their condition (1-7 scale 1: greatly worsened and 7: greatly improved), feelings before/after their most recent surgery (1-5 scale, 1: completely disagree, 5: completely agree with presented statements), and treatment preference questions.
Results
Data collected from 220 pts (68% female, median age 40 years, median disease duration 16 years) in US (n=108), CA (n=37), UK (n=21), FR (n=3), and DE (n=51). 146 pts reported RCC (66%), 122 pNET (56%), and 190 CNS-Hb (86%). 205 (93%) pts had experienced surgery; 171 (78%) had experienced multiple surgeries (median = 4). Top three concomitant self-reported conditions were anxiety (36%), depression (29%) and high blood pressure (28%). 24% of pts consulted a mental health specialist. 51% of pts indicated that their most recent surgery worsened their mental health (rated 1-3), 84% of pts agreed they felt anxious before their most recent surgery (rated 4-5). After their most recent surgery 50% of pts agreed they felt anxious. 33% of pts indicated improving quality of life was in their top 3 treatment goals; 17% indicated improving mental wellbeing was in their top 3 treatment goals. 73% of patients indicated they would prefer to take a pill which would possibly delay time until surgery, rather than watch and wait to see if the tumor would grow.
Conclusions
Pts with VHL-associated disease report anxiety and depression as the most common mental health conditions, and agree that upcoming surgery worsens their anxiety. Over half of pts reported that their most recent surgery worsened their mental health. Despite this, less than a quarter of pts consulted a mental health specialist.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Merck.
Funding
Merck.
Disclosure
O. Iliopoulos: Financial Interests, Personal, Speaker, Consultant, Advisor: Merck, C4 Therapeutics. C. Atkinson, C. Cooper, G. Taylor-Stokes: Financial Interests, Institutional, Sponsor/Funding, Received funding from Merck to conduct the study: Adelphi Real World. J. Mann: Financial Interests, Personal, Stocks/Shares: Merck. M. Sundaram: Financial Interests, Personal, Full or part-time Employment: Merck; Financial Interests, Personal, Stocks/Shares: Merck, BMS, AbbVie, J&J.
Resources from the same session
77P - Normative data on the sexual health questionnaires - QLQ-SHQ22, and the sexual domains of the QLQ-BR23/BR45 - for Norwegian general population with and without cancer
Presenter: Ragnhild Åsberg
Session: Poster session 09
78P - Peroxiredoxin-1 knockout negatively affects the viability of ph+ B-cell acute lymphoblastic leukemia cells and sensitizes them to tyrosine kinase inhibitors
Presenter: Jaromir Hunia
Session: Poster session 09
79P - Co-delivered crizotinib and gefitinib based on nanoparticle for synergically overcoming resistance lung adenocarcinoma treatment
Presenter: Haiyu Zhou
Session: Poster session 09
80P - Steroidal oximes: A new potential therapeutic approach for cancer treatment
Presenter: Mafalda Laranjo
Session: Poster session 09
81P - miR-23b and -133a role on TRAIL-induced apoptosis pathway components expression and TRAIL sensitization in lung adenocarcinoma cells
Presenter: Denise Leite
Session: Poster session 09
84P - Microenvironment immune differences between sexes in multiple myeloma
Presenter: Maria de los Angeles Clavo
Session: Poster session 09
85P - In silico evaluation of the transcriptomic and immunologic profile of lung adenocarcinomas with deletions or disruptive mutations of SMARCA4
Presenter: Ester Garcia Lorenzo
Session: Poster session 09
86P - Effect of chemotherapy-induced autophagic secretome on natural killer cell activity
Presenter: Ayfer Karlitepe
Session: Poster session 09
87P - WIP1 phosphatase promotes etoposide induced autophagy in medulloblastoma and neuroblastoma
Presenter: Hatice Pilevneli
Session: Poster session 09
88P - PPM1D/WIP1 phosphatase mediates basal and genotoxic stress-induced autophagy via ULK-1 de-phosphorylation
Presenter: Ceylan Ak
Session: Poster session 09